Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate

Seoul National University Hospital40 enrolled

Overview

The purpose of this study is to determine whether dutasteride may influence the expression of angiogenesis factors such as hypoxia inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF) in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH).

A total of 41 patients awaiting transurethral resection of the prostate (TURP) will be divided into two groups (1:1); twenty patients will receive no medication and 21 will receive 0.5 mg dutasteride daily for 2 to 4 weeks until TURP. In both groups, the extent, intensity and intracellular location of hypoxia inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)will be evaluated. Microvessel density will be also compared in the two groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Benign Prostatic Hyperplasia

Interventions

dutasterideDRUG

5mg, oral, daily, 2-4 weeks

Eligibility

Sex: MALEMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * informed consent * 50 years old or older * International Prostate Symptom Score (IPSS) \>8 * Maximum flow rate (Qmax) \<15 ml/s * transurethral resection of the prostate (TURP) Exclusion Criteria: * urethral catheter * urinary tract infection (UTI) * liver disease * renal disease * unexplained hematuria * prostate specific antigen (PSA) \> 4ng/ml (included if prostate biopsy was negative) * interstitial cystitis * bladder cancer or prostate cancer * pelvic surgery or irradiation

Outcomes

Primary Outcomes

HIF-1a and VEGF expression

effects of dutasteride on the expression of angiogenesis markers in rat and human prostates

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.